By IDSE News Staff
ATLANTA—PRO 140, an investigational HIV treatment, shows effective, long-acting viral suppression when it is used in combination with antiretroviral therapy (ART) for previously treated HIV-1–infected patients, according to a presentation at ASM Microbe 2018 (abstract AAR LB15).
The study is an ongoing randomized, double-blind, placebo-controlled trial. PRO 140 is a novel humanized CCR5 monoclonal antibody under development by CytoDyn Inc., as a simple,